Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SEMA4A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SEMA4A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SEMA4A Products |
| Gene Delivery | SEMA4A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SEMA4A Products |
| Benchmark Ab | Anti-SEMA4A Recombinant Antibody Recombinant positive control derived from clinical-stage sequences. |
View SEMA4A Products |
| Validator | SEMA4A siRNA Set For knockdown verification. |
View SEMA4A Products |
| Related Target A | PLXNB1 (Plexin-B1) Primary functional receptor for SEMA4A, critical for downstream signaling and migration assays. |
View PLXNB1 Products |
| Related Target B | LILRB2 (ILT4) Immune inhibitory receptor interacting with SEMA4A to mediate myeloid-derived suppression. |
View LILRB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Binding Specificity (Plexins vs. LILRB2) | HEK293 Expressed (Native Glycosylation) SEMA4A ECD-Fc with verified receptor-binding conformation. |
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus SEMA4A ortholog proteins available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SEMA4A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SEMA4A therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecifics and combination therapies in the tumor microenvironment. As first-generation therapies reach the clinic, the next wave of R&D is targeting SEMA4A-mediated immune evasion and angiogenesis bypass pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Onco-immunology Biotechs | Solid Tumors, Autoimmune Diseases | Receptor blocking assays (Need high-purity SEMA4A ECD-Fc) |
| Bispecific Antibody | Checkpoint Combination Developers | Metastatic Cancers, Refractory Tumors | Dual-targeting binding assays (Need SEMA4A and co-target proteins) |
| Small Molecule Inhibitors | Academic Spin-offs | Angiogenesis-driven Disorders | Selectivity Assay (Need Mutant vs WT Proteins) |